PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique en phase clinique, spécialisée dans le développement et la comme…
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Uncategorized
Multiple studies show benefit of NCX 470 in glaucoma
Three studies presented at the American Glaucoma Society meeting demonstrated the potential benefit of NCX 470 in patients with glaucoma.NCX 470 (Nicox) is a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with glaucoma. Sa…
Uncategorized
Medical groups double down on lobbying amid health policy shakeups
Major health care policy changes under the Trump administration have driven some professional medical organizations to take different approaches to their advocacy strategies.During President Donald J. Trump’s second term, the administration has launche…
Could Blood Pressure Meds Worsen Glaucoma Damage?
Patients with glaucoma who had low 24-hour systemic blood pressure were more likely to lose retinal nerve fiber layer despite well-controlled intraocular pressure. Medscape Medical News
Pediatric Rheumatologist Explains Updated ACR JIA Guidelines
The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side effects in growing children,’ said rheumatologist Susan Shenoi, MS. Medscape Medical News